Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Dec 01, 2022 / 07:15PM GMT
Release Date Price: R$29.37
Gavin Clark;Gartner
Evercore ISI Institutional Equities, Research Division - Analyst

All right. Welcome, everyone. This is Gavin Clark-Gartner from the Evercore ISI Biotech Research team, and I'm very happy to be here with Doug Ingram, the President and CEO of Sarepta Therapeutics. Doug, thanks for joining us.

Questions & Answers

Gavin Clark;Gartner
Evercore ISI Institutional Equities, Research Division - Analyst

Only have 20 minutes for this fireside, so we're going to dive straight into the Q&A. Your first question, focusing on 9001, micro-dystrophin gene therapy for LGMD, starting on the regulatory and clinical aspects, especially with the Study 102, with the initial cohort that was underdosed, have you done any post-hoc analyses to correlate micro-dystrophin expression to functional benefit?

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

We have done a number of analytics. So first of all, we've done a number of analytics to look

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot